REG - Nuformix PLC - NXP002 Update

NuformixAnnouncement

09/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250409:nRSI1997Ea&default-theme=true

RNS Number : 1997E  Nuformix PLC  09 April 2025

9 April 2025

 

Nuformix plc

("Nuformix" or the "Company")

 

NXP002 Update

 

Positive results from analysis of lung tissue from IPF and autoimmune ILD
patients

 

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce results following the re-analysis of data from previous studies of
NXP002 in a precision-cut lung slice ("PCLS") disease model using tissue
explanted from lung-transplant receiving patients with idiopathic pulmonary
fibrosis ("IPF") and autoimmune-related interstitial lung disease ("ILD").

 

The data re-analysis undertaken was an outcome of on-going discussions with
potential licensing and development partners for NXP002. In addition to
patients with IPF and progressive pulmonary fibrosis ("PPF"), patients
suffering from autoimmune ILDs (e.g. rheumatoid arthritis or systemic
scleroderma) also have a high-mortality progressive fibrotic disease course
which is not currently adequately treated.

 

In addition to lung tissue from seven IPF patients, NXP002 has been studied in
tissue from an autoimmune ILD explanted lung (in this case from a patient
diagnosed with non-specific interstitial pneumonia or NSIP). This data was
revisited to compare key biomarker changes in tissue in response to NXP002
treatment using an 'area under the curve' (AUC) based approach, considering
total biomarker expression during the treatment period. These new results are
summarised as follows:

 

·    A clear dose response to NXP002 was observed across both extra
cellular matrix ("ECM") biomarkers and pro-fibrotic mediators suggesting
NXP002's activity in additional pathways to standards of care;

·    A consistent and significant effect of NXP002 was observed alone and
in combination with standards of care across both biomarker types in all
donors;

·    When the Col1A1 gene was found to be overexpressed in tissue,
representing active fibrotic disease and tissue turner, NXP002 consistently
attenuates it's expression. When Col1A1 is not overexpressed Col1A1 is
maintained, which may point towards NXP002's role in ECM homeostasis and
supporting healthy tissue repair and regeneration, consistent with the
evidence base describing positive results from clinical studies of tranilast
in a range of fibrotic diseases; and

·    The autoimmune-ILD donor studied also showed a significant response
across both biomarker types alongside the seven IPF donors confirming that
NXP002's activity translates well to autoimmune-derived ILDs.

Dr Dan Gooding, Executive Director, Nuformix, said: "The PCLS lung tissue
model has become the gold-standard disease model thanks to various
close-to-patient benefits. We believe the dataset we have generated, in what
we believe is one of the largest IPF patient tissue sample sets studied, gives
us great confidence in NXP002. In what is a highly variable and heterogenous
disease, to see such consistent activity across all donors towards
pro-fibrotic mediators in both IPF and autoimmune ILD is impressive. The
emergence of data supporting additional activity towards Col1A1 overexpression
is exciting because this profile would be in contrast to high-potency, single
target therapeutics, whose activity may negatively impact healthy tissue
repair processes, leading to increased risk in long term use as observed in
numerous recent IPF clinical studies. For patients with ILD's of an autoimmune
origin, given such patients' background systemic therapies, an inhaled
approach towards treatment would be highly advantageous in both development
and treatment. We are excited by the results and continue discussions with
potential partners, who also see advantages in NXP002 in terms of therapeutic
optionality and future product positioning. I look forward to providing
further updates in due course."

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director  Via IFC Advisory

 CMC Markets
 Douglas Crippen                     +44 (0) 20 3003 8632

 IFC Advisory Limited
 Tim Metcalfe                        +44 (0) 20 3934 6630

 Zach Cohen                          nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities.  Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQVLFBEZLXBBF